Stories

Dakota-Scott Workforce Development Board named Prime a 2019 Employer of Excellence

Prime recognized for excellence in employee retention, compensation and training practices

August 22, 2019
Prime earned a place on the Dakota-Scott Workforce Development Board’s fourth annual list of Employers of Excellence in the large employer category. The program recognized 12 employers in Dakota and Scott counties for exemplary practices to attract and retain employees. The survey highlighted Prime’s assets in the talent acquisition space including:

  • Engagement surveys
  • Action planning
  • Leadership communication channels and
  • Use of collaboration spaces

Participants completed a 40-question survey that allowed their employment practices to be analyzed by a consulting firm. Employers were ranked in 37 categories including rate of employee growth, benefits offered, paid days off and increase in pay.

Recipients were recognized at the Employers of Excellence event on Aug. 15 in Savage, MN. The full list of recipients is available online in Dakota County’s newsroom.

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Read More

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Read More

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion

Read More
View all news